.png)
.png)
Latest news from BIA
BIA comment on Government response to the Health Committee’s report on Brexit and medicines, medical devices and substances of human origin
The BIA has commented on the Government’s response to the Health Committee’s report on Brexit and medicines, medical devices and substances of human origin.
Life Sciences sector responds to the Business, Energy and Industrial Strategy (BEIS) Committee report on the impact of Brexit on the pharmaceutical sector
A report published today [Thursday 17 May] by the BEIS Strategy Committee, calls on the Government to secure a post-Brexit deal to protect the patients in the UK and the UK's pharmaceutical industry.
BIA calls for new fund to democratise opportunities to invest in biotech
The BioIndustry Association (BIA) has called on the government to introduce a new venture capital fund structure that will give the public the opportunity to be partners in the UK’s biotech revolution. The fund should be based on the successful Enterprise Innovation Scheme (EIS) and include a new “Holding Relief”, which will reward individuals with further income tax relief if they stay invested in the long-term.
UK Bioindustry Association and the Royal College of Physicians announce new collaboration
The BioIndustry Association and the Royal College of Physicians of London (RCP) have announced a collaborative partnership, offering both memberships increased opportunities to engage on issues such as innovation, access to the NHS and regulation.
Humans on a chip – the future for research and drug discovery
Medicines Discovery Catapult, the Centre for Drug Safety Sciences at the University of Liverpool and the NC3Rs combine forces to propel the UK into the race to advance organ on a chip technology
PredictImmune join the Babraham Research Campus community
Developer of pioneering tools for guiding treatment options in immune-mediated inflammatory diseases choose Babraham Research Campus as permanent base within the Cambridge Cluster
Crescendo Biologics Raises $70m in Series B Financing
Crescendo are delighted to be celebrating our $70 Million (€57 Million) Series B Financing with investment from new investors, Andera Partners and Quan Capital, and continuing support from existing investors Sofinnova Partners, IP Group, EMBL and Takeda Ventures. The funds will be used to advance the development of our lead programme, CB307 a novel targeted T-cell engager which stimulates local activation of tumour-specific T-cells, and further expand our internal pipeline of Humabody® products.
Astex’s Harren Jhoti made Fellow of the Royal Society
Cambridge, UK - Astex Pharmaceuticals (“Astex”), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, announced today that Harren Jhoti Ph.D., co-founder of Astex and President and CEO of Astex Pharmaceuticals (UK) has been elected a Fellow of the Royal Society in recognition of his outstanding contribution to drug discovery research and science in general.
Guest blog: ‘Diversity in STEM: why it matters more than ever’ – By Gillian Burgess
Dr Gillian Burgess, Site Head of UK Research and Vice President at Vertex Pharmaceuticals and Board Member of the Science Industry Partnership (SIP) of employers, sets out the business case for keeping up the momentum on diversity across the science industries.
BIA analysis of the Office for Life Sciences 'Strength and Opportunity' and 'Life Sciences Competitiveness Indicators' data
Last week the government produced two reports looking at the vital statistics of the UK life sciences industry and the international competitiveness of the UK environment for life sciences businesses. Here we take a brief look at the data and pick out some interesting statistics.
CEO update: Monday 21 May
Today the PM delivered a speech on the vital role AI can have in diagnosing chronic diseases and challenged the NHS, the AI sector and health charities to use data and AI to drastically improve current diagnosis capabilities to prevent 22,000 cancer deaths each year by 2033.
Video of the Week - Getting the most from BIO 2018
Heading to BIO? Watch our latest webinar for tips and guidance on how to make the most of your trip to Boston. We cover everything from transport to networking receptions.
Please find a selection of featured BIA publications below. To see our full publications library, click here.
Influencing and shaping our sector, BIA update: January - April 2018
This quarterly update gives an overview of key policy developments and the BIA’s continued engagement with policymakers, regulatory authorities and wider stakeholders on behalf of the UK life sciences industry, from January to April 2018.
Biotech Financing Update: December 2017 to February 2018
The BIA/Informa Biotech Financing Update: December 2017-February 2018 released today shows that venture capital financing and follow on financing on the public markets are off to a solid start in 2018.
Pipeline Progressing: The UK's Global Bioscience Cluster in 2017
A new report released by the BioIndustry Association (BIA) and Informa Pharma Intelligence reveals that the UK has the strongest clinical and preclinical pipeline in Europe.
BIA Best practice guide for communicating R&D
Ensuring investors and the wider public are well informed and confident about bioscience is crucial to the success of individual companies and the sector as a whole. To support the sector to maintain high standards in communications about R&D progress, the BIA has produced a best practice guide for bioscience companies with a supporting library of resources.
